In re Neogenix Oncology, Inc.

508 B.R. 345, 2014 WL 954124, 2014 Bankr. LEXIS 932
CourtUnited States Bankruptcy Court, D. Maryland
DecidedMarch 11, 2014
DocketNo. 12-23557-TJC
StatusPublished
Cited by9 cases

This text of 508 B.R. 345 (In re Neogenix Oncology, Inc.) is published on Counsel Stack Legal Research, covering United States Bankruptcy Court, D. Maryland primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
In re Neogenix Oncology, Inc., 508 B.R. 345, 2014 WL 954124, 2014 Bankr. LEXIS 932 (Md. 2014).

Opinion

MEMORANDUM OF DECISION

THOMAS J. CATLIOTA, Bankruptcy Judge.

Debtor Neogenix Oncology, Inc. (“Neo-genix” or the “Debtor”), with the support of the Official Committee of Equity Security Holders (the “Committee”), seeks confirmation of its plan of liquidation. Judy A. Robbins, the United States Trustee (“UST”), objects to confirmation. The court previously ruled that the Debtor established all elements for confirmation under 11 U.S.C. § 1129(a)1 with the exception of the two issues addressed herein: (1) whether the plan meets the requirements of § 1129(a)(10), which requires that if any class of creditors is impaired under a plan, at least one class of creditors must approve the plan without regard to the votes of insiders; and (2) whether the plan [349]*349can be confirmed with the third party release and exculpation provisions. The court concludes that the plan meets the requirement of § 1129(a)(10), but further concludes that the third party release provisions cannot be approved under applicable law, and will deny confirmation of the plan as drafted.

The court has subject matter jurisdiction over approval of the confirmation of the plan pursuant to 28 U.S.C. §§ 157 and 1334. The confirmation of a chapter 11 plan is a core proceeding pursuant to 28 U.S.C. § 167(b)(2)(L).

Findings of Fact

The Debtor and the § 363 Sale.

Neogenix is a Maryland corporation founded in 2003 as a biotechnology company that developed therapeutic and diagnostic products in the early detection and treatment of cancer. At the time it filed its petition on July 23, 2012, Neogenix was in the pre-revenue stage; it generated funds almost exclusively from grants and the sale of its common stock, rather than from product sales or operations.

In 2011, Neogenix’s management team learned that prior management and prior counsel had authorized Neogenix to pay finders’ fees to unlicensed or unregistered individuals who raised capital for Neoge-nix. In October 2011, Neogenix received a letter of inquiry from the U.S. Securities and Exchange Commission.2 The letter requested that Neogenix provide information about the finders’ fee payments. Neogenix provided the information requested by the SEC and, by all accounts, has cooperated with the SEC in its investigation.

Neogenix determined that, due to the practice of payment of finders’ fees, some investors may have the right to seek to rescind their stock purchases and require Neogenix to return their investment. Neogenix’s management assessed this risk and determined that it is “reasonably possible” that some shareholders may have rescission rights. As of July 10, 2012, the range of potential liability for rescission was approximately $0 to $31 million. In fact, Neogenix received several shareholder claims for rescission totaling an estimated $1.4 million. However, no rescission litigation against Neogenix has been initiated.

The potential rescission liability jeopardized Neogenix’s on-going business because of the possibility that it might need to rescind stock purchases or pay damages. It also had a chilling effect on Neo-genix’s ability to raise capital. Neogenix appointed a committee to consider available financial alternatives. By March 2012, Neogenix hired Piper Jaffray & Co., to investigate its options to raise capital, or alternatively, search for a buyer. Piper Jaffray conducted a prepetition marketing process and contacted fifty-nine potentially interested parties, but only one party, Precision Biologies, Inc. (“PB”) submitted a bid for Neogenix’s operating assets. PB is a corporation that was formed specifically to purchase Neogenix’s assets, and it was initially owned and managed by Stanley B. Archibald, Jr., who is a shareholder of Neogenix and was also a former Neogenix board member.3 In early February 2012, Archibald resigned and worked on raising [350]*350capital to purchase Neogenix’s operating assets. With the financial support he generated, Archibald formed PB with the goal of purchasing Neogenix.

PB and Neogenix commenced negotiating a potential sale of Neogenix’s assets in May 2012. The sale of Neogenix’s assets to PB was intended to, among other things, provide Neogenix shareholders with an ownership stake in the success of its medical technology.

Neogenix and PB entered into a nonbinding letter of intent in June 2012, and then negotiated the terms of an Asset Purchase Agreement, a bridge loan, and a debtor-in-possession financing facility. An ad hoc committee of Neogenix’s seven largest shareholders, who were not involved in Neogenix’s management and were not owners of PB, helped review and evaluate the proposed purchase. Neoge-nix continued to consult with the ad hoc committee about the sale to PB and about the bankruptcy filing through the petition date.

Neogenix filed for chapter 11 relief on July 28, 2012. On August 7, 2012, the U.S. Trustee appointed seven Neogenix shareholders to serve on the Committee. Two members of the Committee were members of the ad hoc committee, which was disbanded after the Committee was appointed. The Committee retained the law firm of Sands Anderson to serve as its counsel.

The court approved Neogenix’s bid procedures for sale of its assets by an order entered on August 21, 2012. Piper Jaffray re-contacted the original fifty-nine bidders that were identified pre-petition, along with twenty others. Other than PB, there was only one other interested bidder. However, that other interested bidder declined to submit a qualifying bid.

Thus, PB was deemed to be the successful bidder. After notice and a hearing, the court entered a final order approving the sale to PB on September 20, 2013, and the sale closed on September 24, 2012. PB paid Neogenix $3,965,000.00, minus a credit of $1,172,525.37 (representing a payoff of the DIP financing facility) for all of Neoge-nix’s assets. The remaining $2,792,474.63 went to Neogenix, and PB issued Neoge-nix 5.5 million shares of PB stock (the “PB Stock”) to be distributed pro rata to Neo-genix’s shareholders pursuant to a confirmed plan. Contingent cash, in the amount of $730,000, was also lent to Neo-genix, pursuant to the terms of the APA. The only assets that Neogenix maintained were its potential causes of action.

Since the fifing of the case, Neogenix’s directors have not been paid any compensation and officers have not received any compensation after the sale closed to PB.

Plan Provisions.

Neogenix, in consultation with the Committee, developed a chapter 11 plan of liquidation. Ultimately, Neogenix filed an amended disclosure statement, which was approved by the court, and the First Amended Plan of Liquidation (the “Plan”). Docket Nos. 280-81. The court held a confirmation hearing on May 3, 2013, at which it concluded that all elements of § 1129(a) were met for confirmation other than the two issues discussed herein. The parties subsequently filed post-hearing briefs on the two outstanding issues described above.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

ThreeSquare, LLC
N.D. West Virginia, 2023
Retail Group, Inc.
E.D. Virginia, 2021
In re City Homes III LLC
564 B.R. 827 (D. Maryland, 2017)
In re Rexford Properties, LLC
557 B.R. 788 (C.D. California, 2016)

Cite This Page — Counsel Stack

Bluebook (online)
508 B.R. 345, 2014 WL 954124, 2014 Bankr. LEXIS 932, Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-neogenix-oncology-inc-mdb-2014.